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Abstract
Health-related quality of life has become increasingly important in clinical trials over
the past two decades. The R package QoLR is a recently developed package for the
longitudinal analysis of health-related quality of life in oncology. This package contains
the scoring of most of the European Organisation for Research and Treatment of Cancer
quality of life questionnaires and some programs to analyze the time to a health-related
quality of life score deterioration as a modality of longitudinal analysis in oncology.
Keywords: health-related quality of life, longitudinal analysis, time to deterioration, R package
QoLR.
1. Introduction
1.1. Health-related quality of life
Health-related quality of life (HRQOL) is a subjective clinical endpoint that has become in-
creasingly important in clinical trials in oncology over the past two decades (Osoba 2011).
Although overall survival is still considered as the primary objective and the primary end-
point in many studies, most clinical trials now integrate HRQOL as an endpoint in order to
investigate the clinical benefit for the patient. It even seems that HRQOL could become the
primary endpoint in metastatic settings.
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1.2. Assessment
HRQOL is mainly studied through validated questionnaires filled out by the patients at
several timepoints during the study. In oncology, the European Organisation for Research
and Treatment of Cancer (EORTC) has developed a core questionnaire, namely the QLQ-
C30, to assess HRQOL in cancer patients with 30 questions (items) and some supplementary
modules for disease-specific treatment measurements (Aaronson et al. 1993).
The EORTC HRQOL questionnaires are composed of a set of items with several categories
of responses, usually constructed on a Likert scale (e.g., “Not at all”/“a little”/“quite a
bit”/“very much”, coded 1/2/3/4). These questions allow the estimation of one or more
HRQOL dimensions through the calculation of scores. Generally, a score is the weighted sum
of patients’ items responses regarding one dimension and can be calculated if at least half of
the items are answered. The scores are often normalized on a 0–100 scale in order to facilitate
comparison with one or more supplementary HRQOL questionnaires.
For most of the HRQOL questionnaires, a high score corresponds to a high level of functioning
for a functional scale, and to high presence of symptoms for a symptomatic scale. Conversely,
a low score corresponds to a low level of functioning for a functional scale and to low presence
of symptoms for a symptomatic scale. In this way, patients with a high level of HRQOL should
have high scores on functional scales and low scores on symptomatic scales. For questionnaires
that include an item about global health or global HRQOL (as for the EORTC QLQ-C30),
the score obtained is coded like a functional scale.
The method to calculate the scores of the EORTC HRQOL questionnaire is defined in the
EORTC scoring manual (Fayers, Aaronson, Bjordal, Curran, and Grønvold 1999). Briefly, all
the scores of the EORTC HRQOL questionnaires are obtained with the same procedure:
Let I1, . . . , In be the n items answers to the studied dimension.
The first step, common to both functional and symptomatic scales, is the calculation of a raw
score (RS), i.e., the mean of the items:
RS = I1 + · · ·+ In
n
(1)
If there are some missing items, the denominator equals the number of non-missing items.
If more than half the items are missing, the raw score cannot be calculated and then the
dimension score is missing.
The second step is a linear transformation of the scores to a 0–100 scale to obtain a score S:
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1.3. Longitudinal analysis
The longitudinal analysis of HRQOL is a major challenge due to different parameters that
have to be taken into account in the analysis.
Firstly, the longitudinal assessment of HRQOL may be compromised by the presence of
missing data. Two types of missing data can occur: intermittent missing data (e.g., if a
patient forgot to complete one or more questions at one measurement time) or monotone
missing data (e.g., if a patient dropped out before the end of the study). The presence of
missing data can be informative or non-informative of patient’s health status. For example,
if a patient dropped out the study due to disease progression, monotone missing data occur
and can provide information regarding the patient’s HRQOL level: the patient’s HRQOL
level is likely to have decreased. Thus, missing data are missing not at random. Regarding
intermittent missing data, in some circumstances, we can suppose that the patient’s HRQOL
level remains unchanged between two available measures (missing at random or completely
at random).
Secondly, self-assessment of HRQOL is subjective, i.e., it is dependent on the patient’s internal
standards and definition of HRQOL (Wiklund 2004; Bullinger 2002; Ubel, Peeters, and Smith
2010). However, patients’ adaptation to treatment toxicity and their acceptance of the disease
may mean that they do not necessarily assess their HRQOL with the same criteria at all
measurement times. These changes can be reflected by a response shift effect (Gibbons 1999;
Sprangers and Schwartz 1999; Korfage, de Koning, and Essink-Bot 2007) and can bias the
interpretation of longitudinal HRQOL analysis if not taken into account in the study design
or at least in the analysis method (Ahmed, Mayo, Corbiere, Wood-Dauphinee, Hanley, and
Cohen 2005).
Response shift is defined as “a change in the meaning of one’s self-evaluation of a target
construct as a result of: (a) a change in the respondent’s internal standards of measurement
(i.e., scale recalibration); (b) a change in the respondent’s values, i.e., the importance of
component domains constituting the target construct) or (c) a redefinition of the target
construct (i.e., reconceptualization)" (Sprangers and Schwartz 1999). In this way, the choice
of the level of HRQOL reference to qualify a change like deterioration can be a major concern:
the baseline score is not systematically the reference score.
Finally, the longitudinal analysis of HRQOL involves the question of the minimal clinically
important difference (MCID). Indeed, there is a difference between the notion of “statisti-
cally significant” and “clinically significant”. The MCID was defined by Jaeschke, Singer, and
Guyatt (1989) as the smallest change/difference in HRQOL scores perceived as clinically im-
portant. Apart from statistical significance alone, the MCID is a key component that makes
it possible to judge the clinical meaning of the results. Terwee et al. (2010) have reported that
many methods have been proposed to determine the MCID, but no standard has been pro-
posed at this time. These methods are generally grouped in two categories: the anchor-based
and distribution-based methods. The anchor-based methods focus on the relation between
the HRQOL scores and an external criterion that has clinical relevance (Lydick and Epstein
1993). This anchor can be a criterion of disease progression, for example but can also be a pa-
tient’s self-assessment of the global HRQOL change (Jaeschke et al. 1989). Distribution-based
methods are based on the distribution of the HRQOL scores on the obtained sample. For
example, the MCID can then be defined as the half of the standard error (Norman, Sloan,
and Wyrwich 2003) or the standardized response mean (Wyrwich, Nienaber, Tierney, and
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Wolinsky 1999a; Wyrwich, Tierney, and Wolinsky 1999b).
For the EORTC HRQOL questionnaires, Osoba, Rodrigues, Myles, Zee, and Pater (1998)
have demonstrated that a MCID of 5 points is a small change, a change between 10 and 20
points is moderate and more than 20 points indicates very much change. These thresholds
are used for illustration purposes but they are not a gold standard. Moreover, the MCID
can also be questionnaire-specific. More recent and scale-specific guidelines are available for
clinical significance for the EORTC QLQ-C30 (Cocks, King, Velikova, St-James, Fayers, and
Brown 2011).
Due to the complexity of the longitudinal assessment of HRQOL, there is still no gold standard
to analyze HRQOL over time in oncology. Moreover, another challenge of statistical methods
for analyzing longitudinal HRQOL is to propose meaningful results for the clinicians. There
is a need to develop statistical methods adapted for the decision-makers. Longitudinal results
should have the ability to translate findings into information that decision makers find un-
derstandable and compelling. Thus, different methods to analyze longitudinal HRQOL have
been proposed (Pan, Chen, Chung, Wang, Chen, and Hsiung 2012; Hunger, Döring, and Holle
2012; Penar-Zadarko, Binkowska-Bury, Wolan, Gawelko, and Urbanski 2012; Cnaan, Laird,
and Slasor 1997). The most widely used is the linear mixed model (Diggle 1988). Survival
analysis approaches, like the time to deterioration in a HRQOL score, have recently been
proposed as a modality of longitudinal HRQOL analysis in cancer patients (Bonnetain et al.
2010; Hamidou et al. 2011).
The linear mixed model is optimal for a study design with 2 to 5 measurement times (Fair-
clough 2010). In this model, time is considered as a categorical variable. Moreover, these
models are only adapted for studies whose HRQOL assessments are performed in some peri-
ods with few amplitude within patients. In case of a missing not at random profile for missing
data, a pattern mixture model should be applied in order to produce robust results (Pauler,
McCoy, and Moinpour 2003). However, these sub models are rarely applied mainly because
of the complexity of the construction of the patterns. Moreover, at this time, these models do
not deal with the occurrence of a response shift effect. Finally, these models can not provide
results easy to understand for the clinician who is not familiar with the beta change and the
mixed model approach.
Contrary to the linear mixed model, “time to deterioration” (TTD) models can propose clini-
cally meaningful results with hazard ratios and log-rank tests (Bonnetain et al. 2010; Hamidou
et al. 2011). Moreover, these models can handle the presence of missing data: when inter-
mittent missing data occur for one patient, we can consider that the patient’s HRQOL level
remains unchanged since the previous available measure; whereas monotone missing data can
be due to a deterioration of the patient’s health status in case of advanced/metastatic setting.
Finally, these models can take into account the occurrence of the recalibration component
of the response shift effect by choosing different scores as the reference score to qualify the
deterioration (Anota et al. 2013).
The aim of this paper is to present the R (R Core Team 2017) package QoLR which is
available from the Comprehensive R Archive Network at https://CRAN.R-project.org/
package=QoLR. This package makes it possible to calculate the scores of the EORTC QLQ-
C30 and most of its modules and to determine the time to deterioration in a HRQOL score
as a modality of longitudinal analysis.
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2. Time to deterioration definitions
To date, several definitions of TTD in a HRQOL score have been proposed depending on
event definition and censoring rules. The event definition can be defined according to the
reference score, the MCID, missing scores, including death or not. The most intuitive def-
inition is the time from inclusion in the study to a first deterioration of the score with a
MCID of at least k points as compared to the baseline score (Hamidou et al. 2011). Pa-
tients with no deterioration before drop-out from the study are censored at the time of last
HRQOL questionnaire completion or last follow-up. According to the construction of the
score, deterioration corresponds to an increase (e.g., for symptomatic scales of the EORTC
questionnaires) or a decrease (e.g., for functional scales of the EORTC questionnaires) of the
score. Between two available HRQOL scores, the level of HRQOL is supposed to be constant.
The notion of “deterioration” requires a reference score. Generally, the reference score is
the baseline score (before randomization or at inclusion in the absence of randomization).
However, in order to take into account the occurrence of a response shift effect, the reference
can also be
• the best level of HRQOL already experienced by the patient (i.e., the best previous
score);
• or the previous score HRQOL score for the patient (i.e., immediately preceding score).
The value of these scores can change over time according to the patient’s experience of treat-
ment and disease progression. Using these changing references instead of baseline measure-
ment could be considered as an alternative way to take into account the occurrence of the
recalibration component of the response shift effect.
Furthermore, for event definition, we can consider deterioration as definitive (i.e., absorbing
state) or not depending on the therapeutic setting. This induces two concepts: the TTD
and the time until definitive deterioration (TUDD). Several definitions of TUDD have been
proposed, according to the notion of “definitive deterioration”. The TUDD has been defined
as:
1. the time from inclusion in the study to a first deterioration of at least k points as
compared to the reference score,
(a) with no further improvement of more than k points as compared to the reference
score,
(b) or if the time of the deterioration correspond to the last observed HRQOL score,
thus the patient dropped out (i.e., no more HRQOL data available) just after the
deterioration was observed resulting in missing data (Bonnetain et al. 2010).
2. the time from inclusion in the study to a first deterioration of at least k points as
compared to the reference score,
(a) thereafter maintaining this deterioration of at least k points for all following scores,
i.e., the deterioration is observed for all the scores following the first deterioration,
(b) or if the patient dropped out just after the deterioration was observed resulting in
missing data.
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3. the time from inclusion in the study to a first deterioration of at least k points as
compared to the reference score,
(a) with no further improvement of more than k points as compared to the score
qualifying the deterioration (i.e., the score at the time of the first deterioration
observed),
(b) or if the patient dropped out just after the deterioration was observed resulting in
missing data.
To illustrate this, the following equations correspond to the three definitions of TUDD of a
X score with a k-point MCID observed at time i as compared to the reference score Xref
assuming that X represents a functional scale (i.e., a deterioration is observed when the score
decreases):
∃i > 1;Xi ≤ Xref − k and:
1. ∀j > i,Xj ≤ Xref + k for the first definition of TUDD;
2. ∀j > i,Xj ≤ Xref − k for the second definition of TUDD;
3. ∀j > i,Xj ≤ Xi + k for the last definition of TUDD.
For example, if a patient has a reference score equal to 60 points for a functional score
(Xref = 60), then a deterioration with a 5-point MCID as compared to the reference score is
observed at time i if Xi ≤ 55 (Xi ≤ Xref − 5-point MCID). For example, let Xi equal 40.
For each of the three definitions of TUDD previously outlined, this deterioration in time i is
definitive if:
1. ∀j > i,Xj ≤ 65 (Xref + 5-point MCID = 60 + 5) for the first definition of TUDD;
2. ∀j > i,Xj ≤ 55 (Xref − 5-point MCID = 60− 5) for the second definition of TUDD;
3. ∀j > i,Xj ≤ 45 (Xi + 5-point MCID = 40 + 5) for the last definition of TUDD.
Then :
1. if a time k (k > i), Xk = 66 or more, then the deterioration observed at time i is not
definitive according to the first definition of TUDD;
2. if a time k (k > i), Xk = 56 or more, then the deterioration observed at time i is not
definitive according to the second definition of TUDD;
3. if a time k (k > i), Xk = 46 or more, then the deterioration observed at time i is not
definitive according to the last definition of TUDD.
Table 1 indicates the event definition according to the definition of TTD or TUDD retained.
The time until definitive HRQOL score deterioration is mainly applied in advanced or pal-
liative setting. All-cause death can also be considered as an event if the patient did not
experience deterioration before death. In this way, TUDD or death could be redefined as
“HRQOL deterioration-free survival”.
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Reference score Xref at Ti Event definition at Ti
Definition Baseline Best previous score Immediately
MCID = k
points
score Event Event preceding Event = decrease Event = increase
decrease increase score
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•Xj ≥ Xref + k
•∀m > i, Xm ≥ Xi − k
Table 1: Event definitions at time Ti according to the definition of time to score X deterio-
ration as compared to the reference score Xref .
Patients with no score available are excluded from the time-to-deterioration analyses. Patients
with no baseline score are usually censored at baseline and those with no follow up scores but
with a baseline score are censored one day after baseline. As for other analyses of HRQOL,
in the TTD analyses, some sensitivity analyses could be performed:
• Considering patients with no baseline score as events;
• Considering patients with no follow-up score as events;
• Varying the MCID.
For example, let us choose a MCID of 10 points instead of the 5 points initially fixed. Regard-
ing the TUDD, as 5 < 10, then P(TUDD ≥ 5) ≥ P(TUDD ≥ 10), i.e., the probability that a
patient presented a definitive deterioration with 5-point MCID is greater than the probability
that a patient presented a definitive deterioration with a 10-point MCID.
Regarding the TUDD, if a patient experienced a definitive deterioration with a 10-point MCID
but not with a 5-point MCID for any one of the proposed definitions, then this patient must
be considered to have also presented a definitive deterioration with a 5-point MCID, and the
event time will be the time of the 10-point deterioration. Indeed, for patients experiencing a
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Time to deterioration Time until definitive deterioration
including death or not








Definitive deterioration at time T if
A deterioration is observed for all scores
following time T
No clinically significant improvement
as compared to
The reference score






Can be considered as an event:
Patient with no baseline score
Patient with no follow up score
•
•
Figure 1: Flowchart of the choice of definition of time to a health-related quality of life score
deterioration.
TUDD with both a 5-point MCID and a 10-point MCID, the TUDD with a 5-point MCID
must be the time of the first deterioration observed (5-point or 10-point MCID). In this way,
if the deterioration with a 10-point MCID occurs first, we have to impose that the time of
the 5-point deterioration equals the time of the 10-point MCID deterioration.
Figure 1 summarizes the different proposed definitions of TTD and TUDD. To have a valid
observation, we need a date of HRQOL measure and a HRQOL score. When the reference
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score is the best previous score or the immediately preceding score, patients with no baseline
score but with a post baseline score are kept in the TTD analyses if they have at least one
follow up score available after the reference score. They are not censored at baseline. The
first reference score is the first available score.
As TTD analyses belong to survival analyses, the TTD estimation can be calculated using the
Kaplan-Meier or actuarial method and described using median and 95% confidence interval
(CI). The Kaplan-Meier method is based on the intuitive idea that to be alive at time T , one
has to be alive just before time T and not die at time T (Goel, Khanna, and Kishore 2010).
Contrary to the Kaplan-Meier method, in the actuarial method probabilities are estimated
for fixed time intervals, not determined by the date of observed death. Both methods can
handle the presence of censored data, i.e., patients still alive at the end of the study.
In time to deterioration analyses, the event is “HRQOL score deterioration”.







where ni = ni−1 −mi−1 − ci−1 and:
• ni is the number of subjects at risk at time i, i.e., the number of patients still in the
study and who do not present a deterioration until time i− 1;
• mi is the number of events observed at time i, i.e., the number of patients experiencing
a HRQOL score deterioration at time i;
• ci is the number of censored patients at time i, i.e., the number of patients who drop
out at time i and who did not experienced a HRQOL deterioration before.
TTD can then be compared according to treatment arm in case of randomized clinical trials
using the log-rank test and univariate Cox analyses to produce hazard ratios with 95% CI.
Multivariate Cox regression can be applied to identify independent factors associated with
TTD.
The log-rank test is a non-parametric test to compare the survival distributions of two samples
A and B. The null hypothesis H0 is that the survival distribution in both groups A and B are
equal, i.e., the expected probability of the event at time i is the same in both groups. Under
this null hypothesis, the theoretical probability of the event at time i is:
Pi = (EAi + EBi)/(VAi + VBi) (6)
where:
• EAi is the number of observed events in group A at time i;
• EBi is the number of observed events in group B at time i;
• VAi is the number of patients in group A who do not present the event at time i;
• VBi is the number of patients in group B who do not present the event at time i.
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HRQOL scores TTD as compared to TUDD as compared to
Baseline Best previous Immediately preceding








1 2 3 1 2 3 1 2 3
1 61 59 55 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3 T3
2 61 61 56 51 59 T3 T3 T3 T3 T3 T3
3 70 75 73 69 65 T5 T4 T5 T5 T5 T4 T4 T4
4 51 58 50 55 T4 T4 T4 T4 T4 T4
5 64 61 58 47 59 T3 T3 T4 T3 T3 T3 T3 T3 T3 T4
6 69 72 66 T4 T4 T4 T4 T4 T4 T4 T4
7 64 60 57 58 65 T3 T3 T3 T3
8 61 53 61 T4 T4 T4 T4
9 60 62 56 61 57 T3 T3 T3 T5 T3 T3
1055
Table 2: HRQOL scores obtained at 5 timepoints T1 to T5 for 10 patients and time events
according to each definition of TTD and TUDD (1: definition 1; 2: definition 2; 3: definition
3) with a 5-point MCID.
Then the log-rank statistic equals:
χ2exp =









Under the null hypothesis, χ2exp is distributed according to a χ2 distribution with one degree
of freedom.
The Cox regression model link the instantaneous risk of event λ at time t with other covariates
X1, . . . , Xn as follows:




where λ0(t) corresponds to a basic risk and corresponds to an instantaneous risk of event at
time t when all covariates are equal to 0.
sectionIllustrations of the TTD and TUDD definitions Event definition and censoring rules
depend on the definition of deterioration used, as illustrated in both Figure 1 and Table 1.
Table 2 summarizes several situations for patients:
• the variable id is the patient’s identification number;
• T1 to T5 correspond to five HRQOL assessments;
• a deterioration corresponds to a score decrease.
There are some missing scores for several measures, illustrating the issue of intermittent or
monotone missing data in HRQOL studies.
Table 2 illustrates different scenarios according to the event definition. This table summa-
rizes, for each definition of TTD and TUDD, the time of the events for patients experiencing
a deterioration with a 5-point MCID. In other cases, patients are censored at the time of the
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TTD as compared to the baseline score Sensitivity analysis
Id Event Time Event Time
1 1 T3 − T1 1 T3 − T1
2 1 T3 − T1 1 T3 − T1
3 1 T5 − T1 1 T5 − T1
4 0 T5 − T1 0 T5 − T1
5 1 T3 − T1 1 T3 − T1
6 0 T4 − T1 0 T4 − T1
7 0 T5 − T1 0 T5 − T1
8 0 0 1 0
9 0 T5 − T1 0 T5 − T1
10 0 1 1 1
Table 3: Time to deterioration compared to the baseline score with a 5-point MCID for the
patients of Table 2 and sensitivity analysis considering patients with no baseline score or with
no follow up score as events.
last available HRQOL measure. For example, for the TTD as compared to the baseline score,
patients ]4 and ]6 do not present a deterioration and are censored at T5 and T4 respectively.
Patient ]2 presents a deterioration as compared to the baseline score at T3, but not defini-
tive as compared to the score qualifying the deterioration (TUDD.3). Patient ]9 presents a
deterioration as compared to the best score at T3: at T3, the previous best score equals 62
and the difference between this score and the score at T3 is 6, i.e., greater than the MCID.
However, the HRQOL level of the patient goes up to 61 and then the deterioration is not
definitive as compared to the deteriorated score 56. At the last HRQOL assessment, HRQOL
score equals 57 and the previous best score is still 62. In this way, the deterioration observed
at T3 is definitive as compared to the deteriorated score. We recall that if a deterioration is
followed by missing data (patient dropped out), the deterioration is definitive, whatever the
definition of TUDD retained.
Two variables have then been created:
• a dummy variable event indicating if the patient has deteriorated (event = 1) or not
(event = 0);
• a time variable equals to the time between baseline date, and the date of deterioration
or censoring.
Table 3 below illustrates these two variables for the 10 patients of Table 2 and one definition
of time to deterioration.
To illustrate, the patient ]1 is in deterioration as compared to the baseline score (event = 1)
and the time between the baseline date and the date of the deterioration equals T3−T1, then
time = T3 − T1.
Patient ]8 has no baseline score:
• in the primary analysis, this patient is censored at baseline (event = 0);
• in the sensitivity analysis, this patient is in deterioration at baseline (event = 1).
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In both cases, the time to deterioration equals: time = T1 − T1 = 0.
In the same way, patient ]10 has only a baseline score, and no follow-up score:
• in the primary analysis, this patient is censored one day after baseline (event = 0);
• in the sensitivity analysis, this patient is in deterioration one day after baseline (event
= 1).
In both cases, the time to deterioration equals to: time = T1 + 1− T1 = 1.
3. QoLR package
The QoLR package was developed to allow the longitudinal analysis of HRQOL according
to the time to deterioration approach. The QoLR has dependencies with two R packages
(survival, Therneau 2017, and zoo, Zeileis and Grothendieck 2005).
3.1. Package structure
The QoLR package contains a set of functions to calculate the scores of the EORTC QLQ-C30
and most of its modules and two other programs to determine the time to deterioration in
HRQOL score as a modality of longitudinal analysis whatever the definition of deterioration
used. Other programs make it possible to print all of the results or to output in a CSV file
according to treatment arm and perform all sensitivity analyses according to one reference
score. A last program was created to obtain the TTD curves calculated according to the
Kaplan-Meier estimation method, with the option of displaying some information (number of
patients at risk, cumulative number of events, hazard ratio and log-rank test if two treatment
arms are compared).
For the convenience of the reader, we summarize all the main functions, with arguments and
descriptions of our package QoLR in Table 4. Hereafter, we describe some of the package
functions in detail.
Function scoring.QLQC30()
The first application of the QoLR package is the estimation of the scores of most of the
EORTC HRQOL questionnaires, such as the QLQ-C30 cancer specific questionnaire.
The first argument of the function scoring.QLQC30 and other functions for scoring is the name
of the dataset with the items comprising the answers to the questionnaire (X parameter). The
patient’s identification number can be specified in the id parameter. A variable identifying
the HRQOL assessment number can also be specified in the time parameter in case of a
longitudinal HRQOL assessment.
The items must be named q1 to qi for the QLQ-C30 (i = 30), QLQ-C15-PAL (i = 15) and
IN-PATSAT32 (i = 32) questionnaire. For all other supplementary modules, items must be
named q31 to qi, because these modules have to be administered in conjunction with the
QLQ-C30 core questionnaire. For example, items must be named q1 to q30 for the QLQ-C30
and then q31 to q50 for the QLQ-BN20. Moreover, the order of items has to be respected in
the dataset.
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Functions Arguments Description
scoring.QLQC30 (data, id, time) Scoring of the EORTC QLQ-C30 question-
naire
scoring.QLQC15PAL (data, id, time) Scoring of the EORTC QLQ-C15-PAL ques-
tionnaire for palliative care
scoring.QLQBN20 (data, id, time) Scoring of the EORTC QLQ-BN20 module
scoring.QLQBR23 (data, id, time) Scoring of the EORTC QLQ-BR23 module
scoring.QLQCR29 (data, id, time) Scoring of the EORTC QLQ-CR29 module
scoring.QLQCX24 (data, id, time) Scoring of the EORTC QLQ-CX24 module
scoring.QLQELD14 data, id, time) Scoring of the EORTC QLQ-ELD14 module
for elderly cancer patients
scoring.QLQEN24 (data, id, time) Scoring of the EORTC QLQ-EN24 module
scoring.QLQHCC18 (data, id, time) Scoring of the EORTC QLQ-HCC18 hepato-
cellular carcinoma module
scoring.QLQHN35 (data, id, time) Scoring of the EORTC QLQ-H&N35 module
scoring.QLQINFO25 (data, id, time) Scoring of the EORTC QLQ-INFO25 informa-
tion module
scoring.QLQLC13 (data, id, time) Scoring of the EORTC QLQ-LC13 module
scoring.QLQLMC21 (data, id, time) Scoring of the EORTC QLQ-LMC21 liver
metastases in colorectal cancer module
scoring.QLQMY20 (data, id, time) Scoring of the EORTC QLQ-MY20 module
scoring.QLQOES18 (data, id, time) Scoring of the EORTC QLQ-OES18 module
scoring.QLQOG25 (data, id, items) Scoring of the EORTC QLQ-OG25 module
scoring.QLQOV28 (data, id, time) Scoring of the EORTC QLQ-OV28 ovarian
module
scoring.QLQPR25 (data, id, time) Scoring of the EORTC QLQ-PR25 module
scoring.QLQSTO22 (data, id, time) Scoring of the EORTC QLQ-STO22 module
scoring.INPATSAT32 (data, id, time) Scoring of the EORTC IN-PATSAT32 satis-
faction with care questionnaire
TTD (X, score, ...) Estimation of the time to deterioration
TUDD (X, score, ...) Estimation of the time until definitive deteri-
oration
plotTTD (time, event, ...) Kaplan-Meier curve of the TTD or TUDD
write.TTD (X, score, ...) Estimation of the TTD and print the results
in a CSV file
write.TUDD (X, score, ...) Estimation of the TUDD and print the results
in a CSV file
Table 4: Summary of the functions in the QoLR package.
The result is a data frame: each variable corresponds to a HRQOL score. The score names
are the same as those used in the EORTC scoring manual (Fayers et al. 1999). If a patient’s
identification number was specified in the id parameter, then this variable is replicated in
the data frame obtained. Moreover, if a variable identifying the HRQOL assessment number
was specified in the time parameter, then this variable is also replicated in the data frame
obtained.
Function TTD()
This function is used to estimate the time to deterioration of a HRQOL score. To apply this
function, the dataset must respect a general structure. The dataset X must be in long format
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with the following variables in this order:
1. Patient’s identification number;
2. Variable identifying the HRQOL assessment number;
3. Date of HRQOL measure;
4. HRQOL scores;
5. Other variables like the date of death or the treatment arm.
The dataset must also be sorted by patient identification number and HRQOL measurement
time. Dates must be in Julian format (i.e., number of days since a reference time point).
All definitions of TTD presented in this paper are programmed. Table 5 summarizes the ar-
guments of this function and their possible values. According to the definition of deterioration
retained, you must specify the following:
• The name of your dataset (X);
• The name of the HRQOL scores studied (score = " ");
• The value of the MCID (MCID = 5, for example);
• The reference score to qualify the deterioration which can be one of the following:
– The baseline score (ref.init = "baseline");
– The best previous score (ref.init = "best");
– The immediately preceding score (ref.init = "previous").
• Whether the deterioration corresponds to a decrease (order = 1) or an increase of the
score (order = 2);
• Whether patients with no baseline score are excluded (no_baseline = "excluded"),
censored (no_baseline = "censored") or are in deterioration (no_baseline = "event")
since baseline;
• Whether patients with no follow-up score are censored (no_follow = "censored") or
are in deterioration (no_follow = "event") one day after baseline;
• If death is considered as an event, you must specify the name of the variable in your
dataset X which contains the date of death for patients who died during the study and
with missing values for patients still alive at the end of the study.
An option (sensitivity = TRUE) makes it possible to perform all sensitivity analyses avail-
able in one application of the TTD() function.
For example, if you fixed no_baseline = "censored", no_follow = "censored" and
sensitivity = TRUE then:
• A first analysis is conducted censoring patients with no baseline and those with no
follow-up score;
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Arguments Values
X Matrix or data frame
score Vector
MCID Scalar
ref.init = "baseline" (default)/= "best" /= "previous"
order = 1 (default) /= 2
no_baseline = "censored" (default)/= "event" /= "excluded"
no_follow = "censored" (default)/= "event"
death = NA (default) or vector
sensitivity = FALSE (default)/= TRUE
Table 5: Arguments of the TTD function.
• Sensitivity analysis ]1: A sensitivity analysis is conducted considering these patients in
deterioration.
If, in addition to these parameters, the variable death is equals to the variable corresponding
to the date of death in your dataset, then four analyses are performed:
• A first analysis censoring patients with no baseline, those with no follow-up and those
who died without experiencing deterioration before dying;
• Sensitivity analysis ]1: considering patients with no baseline and those with no follow-up
score in deterioration;
• Sensitivity analysis ]2: considering death as an event;
• Sensitivity analysis ]3: considering simultaneously patients with no baseline, those with
no follow-up score and death as an event.
The result of this function is a data frame with:
• the patient’s identification number;
• a dummy variable called event equal to 1 if the patient is deteriorated, 0 if the patient
is censored;
• a variable called time, equal to the time to censoring or the time to deterioration
in months.
Since both variables event and time are created for each score treated and each definition
of TTD, we added the name of the corresponding score as a suffix. For example, if score
= c("score1", "score2"). Then four variables are created: event.score1, time.score1,
event.score2 and time.score2.
Moreover, if sensitivity == TRUE, then added variables event and time are created:
• event.SA1 for sensitivity analysis ]1: event and event.SA1 are equals except for pa-
tients with no baseline score and those with no follow-up score, event.SA1 = 1 while
event = 0. Since time.SA1 == time, then time.SA1 was omitted;
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Arguments Values
X Matrix or data frame with the data
score Vector
MCID Vector
ref.init = "baseline" (default)/= "best" /= "previous"
ref.def = "def1"/= "def2"/ = "def3"
order = 1 (default) /= 2
no_baseline = "censored" (default)/= "event" /= "excluded"
no_follow = "censored" (default)/= "event"
death = NA (default) or vector
sensitivity = FALSE (default)/= TRUE
Table 6: Arguments of the TUDD function.
• event.SA2 and time.SA2 for sensitivity analysis ]2;
• event.SA3 for sensitivity analysis ]3. Since time.SA3 == time.SA2, then time.SA3
was omitted.
Function TUDD()
This function allows the estimation of the time until definitive deterioration according to
the definition retained. All definitions of TUDD presented in this paper are implemented.
The syntax of this function is nearly the same as for TTD. Table 6 below summarizes the
arguments of this function. Only one supplementary parameter is available compared to
the TTD() function, namely: the parameter ref.def in which you can specify the notion of
“definitive deterioration” according to the three definitions proposed in Section 2:
• With no further improvement of at least k points as compared to the reference score
(ref.def = "def1");
• maintaining this deterioration of at least k points for all following scores, i.e., the dete-
rioration is observed for all the following scores (ref.def = "def2");
• with no further improvement of at least k points as compared to the score qualifying
the deterioration (ref.def = "def3").
Moreover, in this function, you can perform sensitivity analysis according to the MCID, thus
the MCID parameter is a vector, not scalar.
Function plotTTD()
The QoLR package also contains a program called plotTTD() to obtain the TTD curves
calculated according to the Kaplan-Meier estimation method for all patients or by treatment
arm (only two groups are allowed). The time parameter is a vector equal to the time to
deterioration or the time to censoring, and the event parameter is a dummy vector equal to
1 if the patient is deteriorated and 0 if not.
Other information can also be added using options, e.g., at regular time point t for all patients
or by treatment arm:




group = NULL (default)/ vector
nrisk = TRUE (default)/= FALSE
nevent = FALSE (default)/= TRUE
group.names = NULL/ vector
t Vector
info = FALSE (default)/= TRUE
pos.info = NULL/ vector
xlab = character
ylab = character
Table 7: Arguments of the plotTTD function.
• number of patients at risk (nrisk = T);
• cumulative number of events (nevents = T).
In the case of TTD curves by treatment arm you must give the name of the group variable
in the group parameter and the label of each group as you would like it to print in the
group.names parameter. The hazard ratio with 95% confidence interval and log-rank test
can also be added on the graph (info = TRUE) at a determined position specified by the user
(pos.info = c()).
xlab and ylab correspond to the name of the horizontal and vertical axis respectively. Table 7
summarizes the arguments of this function.
This function makes it possible to plot the TTD curves with additional information useful for
researchers to easily obtain standard curves for presentation or scientific publications.
Functions write.TTD() and write.TUDD()
These outputs can also be obtained for all definitions of TTD or TUDD with write.TTD() and
write.TUDD() respectively, in the QoLR package. These programs create a comma-separated
values (CSV) file with the results of the TTD or TUDD analyses performed in one or more
scores according to one main deterioration definition. All sensitivity analyses according to
this primary definition are also performed, with one or more MCID, for all patients or by
group (e.g., treatment arm effect). The results produced are as follows:
• the number of patients initially at risk and the number of events;
• the median time to deterioration with 95% confidence interval;
and in the case of analyses performed by group (only two groups are allowed):
• the results of the log-rank test;
• the univariate hazard ratio with 95% confidence interval.
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The arguments of this function are almost the same as the TTD() and TUDD() functions. An
additional parameter corresponds to the name of the file in which to print the results (file
= ""). The user can also specify the directory for this file in the (file = "") parameter.
3.2. Applications of the QoLR package
To apply one or more of these functions, you need to load the QoLR library in the R current
session with the following command:
R> library("QoLR")
We shall demonstrate the use of five main programs of QoLR in one dataset dataqol cor-
responding to a randomized clinical trial with the answers to the 30 items of the QLQ-C30
questionnaire for 40 patients with longitudinal HRQOL assessment. Patients in this table were
randomly allocated to one treatment group corresponding to the variable Arm (dichotomous
variable equal to 0 or 1).
This dataset is available in QoLR package and can be imported into R via the command
data("dataqol").
This dataset contains the following information:
• the patient identification number in the Id parameter;
• the treatment group to which each patient was allocated, corresponding to the variable
Arm (dichotomous variable equals to 0 or 1);
• a variable indicating the theoretical HRQOL assessment number in the time parameter
(equal to 0 for baseline measure);
• the date of HRQOL assessment in the date parameter;
• and the answers to the 30 items of the QLQ-C30 in the variables q1 to q30;
• and the date of death for patients who died during the study in the death parameter
(missing for all patients who were still alive at the end of the study).
This dataset is in long format. The variable date corresponds to the date of HRQOL measure
in Julian format. The baseline date was set to 0 and all the following dates correspond to
the time between the measure and the baseline date (the baseline date is the date of origin).
HRQOL was evaluated about every 50 days. In the same way, death corresponds to the time
between the baseline date and the date of death if the patient died during the study. Moreover,
some items and/or measurement times are missing in order to illustrate how missing data are
treated in the scoring and then in the Time to deterioration analysis.
This dataset looks like the following:
R> data("dataqol")
R> head(dataqol)
Id Arm time date q1 q2 q3 q4 q5 q6 q7 q8 q9 q10 q11 q12 q13 q14 q15 q16 q17
1 1 2 0 0 1 2 NA 2 1 2 1 1 2 2 3 2 1 3 3 2 2
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2 1 2 1 43 3 4 3 3 1 2 2 2 1 4 2 4 3 3 3 3 3
3 1 2 2 92 2 2 1 2 1 2 2 1 2 2 2 3 3 2 2 2 2
4 2 2 0 0 1 1 1 1 1 1 1 1 2 3 4 3 4 1 1 4 1
5 2 2 1 55 2 3 2 2 1 1 1 1 NA 3 3 3 3 1 1 4 1
6 2 2 2 149 2 3 2 2 2 1 1 2 2 3 3 4 3 1 1 4 1
q18 q19 q20 q21 q22 q23 q24 q25 q26 q27 q28 q29 q30 death
1 2 2 1 2 4 2 3 1 2 2 1 5 4 NA
2 4 3 2 3 3 3 3 1 1 4 1 3 3 NA
3 2 2 2 3 3 2 3 1 2 3 2 4 4 NA
4 3 2 1 2 3 3 3 1 1 2 1 4 4 271
5 3 1 2 1 3 3 2 1 1 3 1 4 5 271
6 3 2 2 2 3 3 2 1 1 3 1 4 4 271
Scoring EORTC questionnaires
We illustrate the use of the program scoring.QLQC30() to estimate the score of a QLQ-C30
questionnaire in the dataqol dataset.
To apply the scoring.QLQC30() program, you have to specify at least the name of the dataset.
You can also specify a patient’s identification number in the id parameter as well as a time’s
identification number in the time parameter. The result is a data frame score_dataqol in
which each variable corresponds to a score of the questionnaire, the first variable is the id
parameter and the second one is the time parameter if they are filled in:
R> score_dataqol <- scoring.QLQC30(dataqol, id = "Id", time = "time")
R> head(round(score_dataqol))
Id time QL PF RF EF CF SF FA NV PA DY SL AP CO DI FI
1 1 0 58 83 83 42 100 67 33 67 33 0 67 0 33 33 0
2 1 1 33 40 67 33 83 50 100 67 33 33 33 67 67 67 0
3 1 2 50 80 67 42 83 50 44 33 33 0 33 67 33 33 33
4 2 0 50 100 100 42 100 83 67 0 33 0 100 100 100 0 0
5 2 1 58 67 100 58 83 67 67 0 0 0 67 67 100 0 0
6 2 2 50 60 100 50 83 67 78 0 33 33 67 67 100 0 0
Then, we can illustrate the TTD and TUDD functions.
Time to HRQOL score deterioration
Time to deterioration. To apply the TTD function, we have to first modify the
scoring_dataqol dataframe in order to respect the requested format of the TTD function.
As a reminder, this dataset must contain the following information in the following order:
1. Patient identification number;
2. Variable identifying the HRQOL assessment number with value 0 for the baseline mea-
sure;
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3. Date of HRQOL measure;
4. HRQOL scores;
5. Other variables, such as the date of death or the treatment arm.
The date of HRQOL assessment as well as the treatment arm and date of death are available
in the dataqol dataset. We thus merged the score_dataqol dataframe with the important
variables of the dataqol dataframe as follows:
R> info <- dataqol[, c("Id", "time","date", "death", "Arm")]
R> dataqol_final <- merge(score_dataqol, info, by = c("Id", "time"))
Id time QL PF RF EF CF SF FA NV PA DY SL AP CO DI FI date death Arm
1 1 0 58 83 83 42 100 67 33 67 33 0 67 0 33 33 0 0 NA 2
2 1 1 33 40 67 33 83 50 100 67 33 33 33 67 67 67 0 43 NA 2
3 1 2 50 80 67 42 83 50 44 33 33 0 33 67 33 33 33 92 NA 2
4 10 0 25 50 67 42 0 17 100 50 67 0 0 100 100 0 67 0 NA 1
5 10 1 17 33 67 25 67 17 100 67 83 0 67 100 0 100 67 56 NA 1
6 11 3 67 80 83 75 100 67 33 17 33 0 0 33 0 0 33 150 273 2
Then we reorganized the obtained dataqol_final dataset in order that the date variable
appeared in third position:
R> dataqol_final <- dataqol_final[, c(1:2, 18, 3:17, 19:20)]
R> head(round(dataqol_final))
Id time date QL PF RF EF CF SF FA NV PA DY SL AP CO DI FI death Arm
1 1 0 0 58 83 83 42 100 67 33 67 33 0 67 0 33 33 0 NA 2
2 1 1 43 33 40 67 33 83 50 100 67 33 33 33 67 67 67 0 NA 2
3 1 2 92 50 80 67 42 83 50 44 33 33 0 33 67 33 33 33 NA 2
4 10 0 0 25 50 67 42 0 17 100 50 67 0 0 100 100 0 67 NA 1
5 10 1 56 17 33 67 25 67 17 100 67 83 0 67 100 0 100 67 NA 1
6 11 3 150 67 80 83 75 100 67 33 17 33 0 0 33 0 0 33 273 2
Finally, in order to apply the TTD function, the dataset has to be sorted by patient’s identifi-
cation number (Id) and HRQOL measures (time):
R> dataqol_final <- dataqol_final[order(dataqol_final$time), ]
R> dataqol_final <- dataqol_final[order(dataqol_final$Id), ]
R> head(round(dataqol_final))
Id time date QL PF RF EF CF SF FA NV PA DY SL AP CO DI FI death Arm
1 1 0 0 58 83 83 42 100 67 33 67 33 0 67 0 33 33 0 NA 2
2 1 1 43 33 40 67 33 83 50 100 67 33 33 33 67 67 67 0 NA 2
3 1 2 92 50 80 67 42 83 50 44 33 33 0 33 67 33 33 33 NA 2
25 2 0 0 50 100 100 42 100 83 67 0 33 0 100 100 100 0 0 271 2
26 2 1 55 58 67 100 58 83 67 67 0 0 0 67 67 100 0 0 271 2
27 2 2 149 50 60 100 50 83 67 78 0 33 33 67 67 100 0 0 271 2
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Since HRQOL was measured at several measurement times for each patient, we can study
the time to deterioration of the HRQOL scores.
As a reminder, for global health status (variable QL) and other functional scales (variables
PF for physical functioning to SF for social functioning) a high score reflects a high level of
HRQOL or functioning. For symptomatic scales (variables FA for fatigue to FI for financial
difficulties), a high score reflects a high symptomatic level.
To begin, we can study the reference definition of TTD of the QL score, i.e., a deterioration as
compared to the baseline score (ref.init = "baseline") with at least 5-point MCID (MCID
= 5) and considering patients with no baseline or with no follow-up measure censored at base-
line or just after baseline (no_baseline = "censored" and no_follow = "censored"). The
score QL corresponds to a measure of global HRQOL. In this way, a deterioration corresponds
to a decrease of the score (order = 1). Since the values of these parameters are the default
values (except for the MCID), we do not need to specify their values and the function can
thus be applied as follows:
R> ttd1 <- TTD(dataqol_final, score = "QL", MCID = 5)
R> head(ttd1)
Id event.QL time.QL
1 1 1 1.41273101
2 2 0 4.89527721
3 3 1 1.77412731
4 4 0 0.03285421
5 5 0 0.00000000
6 6 1 1.70841889
The result is a data frame with the identification number of patients (Id), the time to dete-
rioration or to censoring in months (time.QL) and a dummy variable (event.QL) indicating
whether the patient is deteriorated (event.QL = 1) or not (event.QL = 0). The suffix “QL”
corresponds to the name of the treated score. According to this definition, 24 patients are
deteriorated among the 40 patients in terms of the QL score:
R> sum(ttd1$event.QL, na.rm = TRUE)
[1] 24
If we want to consider patients with no baseline or no follow up as events, we have to fix the
parameters no_baseline and no_follow to "event" as follows:
R> ttd2=TTD(dataqol_final, score = "QL", order = 1, MCID = 5,
+ no_baseline = "event", no_follow = "event")
R> head(ttd2)
Id event.QL time.QL
1 1 1 1.41273101
2 2 0 4.89527721
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3 3 1 1.77412731
4 4 1 0.03285421
5 5 1 0.00000000
6 6 1 1.70841889
R> sum(ttd2$event.QL, na.rm = TRUE)
[1] 33
9 patients with no baseline or no follow-up measure are then added to the events.
To consider death as an event, we have to specify the value of the death parameter:
R> ttd3 <- TTD(dataqol_final, score = "QL", MCID = 5, death = "death")
R> head(ttd3)
Id event.QL time.QL
1 1 1 1.412731
2 2 1 8.903491
3 3 1 1.774127
4 4 1 1.018480
5 5 0 0.000000
6 6 1 1.708419
Finally, we can obtain directly all the sensitivity analyses along with the primary analysis in
one application of the function TTD by specifying sensitivity = TRUE:
R> ttd4 <- TTD(dataqol_final, score = "QL", MCID = 5, death = "death",
+ sensitivity = TRUE)
R> head(ttd4)
Id event.QL time.QL event.SA1.QL event.SA2.QL time.SA2.QL event.SA3.QL
1 1 1 1.41273101 1 1 1.412731 1
2 2 0 4.89527721 0 1 8.903491 1
3 3 1 1.77412731 1 1 1.774127 1
4 4 0 0.03285421 1 1 1.018480 1
5 5 0 0.00000000 1 0 0.000000 1
6 6 1 1.70841889 1 1 1.708419 1
When all sensitivity analyses are performed, some added variables are created. Variables
event.QL and time.QL still correspond to the results of the primary analysis (TTD as com-
pared to the baseline score in the present case). The variable event.SA1.QL is the dummy
event variable considering patients with no baseline or no follow up measure in deterioration
since baseline, whereas they were censured in the primary analysis (Sensitivity Analysis ]1).
Since the corresponding times are the same as in the primary analysis, no new time vari-
able was created. Variables event.SA2.QL and time.SA2.QL are the results for the analysis
adding death as an event (Sensitivity Analysis ]2). Finally, event.SA3.QL corresponds to the
event variable with death and patients with no baseline or no follow up as events (Sensitivity
Analysis ]3).
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In order to integrate the response shift effect, we can choose the best previous HRQOL score
or the immediately preceding score as the reference score by specifying ref.init = "best"
or ref.init = "previous" respectively.
In the following example, the reference score is the best previous QL score:
R> ttd5 <- TTD(dataqol_final, score = "QL", MCID = 5, ref.init = "best")
R> head(ttd5)
Id event.QL time.QL
1 1 1 1.41273101
2 2 1 4.89527721
3 3 1 1.77412731
4 4 0 0.03285421
5 5 0 1.34702259
6 6 1 1.70841889
R> sum(ttd5$event.QL, na.rm = TRUE)
[1] 26
In this case, 26 patients experienced a deterioration as compared to the best previous QL score
The function TTD() can handle many scores simultaneously, functional and/or symptomatic
scores. You must define the name of the scores studied in the score parameter as well as the
order to consider (i.e., decrease or increase): order = 1 for global health status or functional
scales and order = 2 for symptomatic scales. Variables event and time are then created for
each score with the score name as a suffix. The following example represents the application
of the TTD function as compared to the baseline score with a 5-point MCID for QL, PF (with
order = 1 for both scores) and FA (with order = 2):
R> ttd6 <- TTD(dataqol_final, score = c("QL", "PF", "FA"), order = c(1, 1, 2),
+ MCID = 5)
R> head(ttd6)
Id event.QL time.QL event.PF time.PF event.FA time.FA
1 1 1 1.41273101 1 1.41273101 1 1.41273101
2 2 0 4.89527721 1 1.80698152 1 4.89527721
3 3 1 1.77412731 0 5.15811088 0 5.15811088
4 4 0 0.03285421 0 0.03285421 0 0.03285421
5 5 0 0.00000000 0 1.34702259 0 0.00000000
6 6 1 1.70841889 1 1.70841889 1 1.70841889
Time until definitive deterioration. The TUDD is studied with the TUDD() function,
quite similar to the TTD() function. By default, the deterioration is defined as a deterioration
with a k-point MCID as compared with the baseline score, with no further improvement of
more than k points as compared to the baseline score (Bonnetain et al. 2010). The result of
the application of this function is fairly similar to that of the TTD(). However, for TUDD(),
the value of the MCID is also specified in the variable names time and event.
The result of the reference definition of TUDD is as follows:
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R> tudd1 <- TUDD(dataqol_final, score = "QL", MCID = 5)
R> head(tudd1)
Id event.5.QL time.5.QL
1 1 1 1.41273101
2 2 0 4.89527721
3 3 1 1.77412731
4 4 0 0.03285421
5 5 0 0.00000000
6 6 0 11.49897331
R> sum(tudd1$event.5.QL, na.rm = TRUE)
[1] 22
Thus, 22 patients experienced a definitive deterioration as compared to the baseline score
according to the definition of Bonnetain et al. (2010).
The deterioration can also be definitive as compared to the deterioration observed, i.e., with
no further improvement of 5-point MCID as compared to the score obtained at the time of
the first deterioration. This definition is applied by setting the parameter ref.def to the
value "def3":
R> tudd2 <- TUDD(dataqol_final, score = "QL", MCID = 5, ref.def = "def3")
R> head(tudd2)
Id event.5.QL time.5.QL
1 1 1 3.02258727
2 2 0 4.89527721
3 3 0 5.15811088
4 4 0 0.03285421
5 5 0 0.00000000
6 6 0 11.49897331
As for the TTD, all sensitivity analyses can be performed simultaneously with the primary
definition of TUDD. Moreover, many MCID can be specified. In fact, as defined in section
2, we need a dependence between sensitivity analyses varying the MCID for TUDD. An
indicator of the MCID value is added as a suffix of the resulting parameters event and time.
The following example is based on the physical functioning score (PF):
R> tudd3 <- TUDD(dataqol_final, score = "PF", MCID = c(5,10),
+ sensitivity = TRUE)
R> head(round(tudd3, 2))
Id event.10.PF time.10.PF event.10.SA1.PF event.5.PF time.5.PF event.5.SA1.PF
1 1 1 1.41 1 1 1.41 1
2 2 1 1.81 1 1 1.81 1
3 3 0 5.16 0 0 5.16 0
4 4 0 0.03 1 0 0.03 1
5 5 0 1.35 0 0 1.35 0
6 6 0 11.50 0 1 1.71 1
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Figure 2: Kaplan-Meier survival curve for the time until definitive QL score deterioration of
at least 5-point MCID as compared to the baseline score.
In this application, death has not been taken into account. Only two sensitivity analyses
were performed: the first regarding patients with no baseline or no follow-up measure and
the second on the MCID value.
Time to deterioration curves. Figure 2 corresponds to the TUDD of QL score as com-
pared to the baseline score with a 5-point MCID according to treatment arm (Arm parameter).
In this graph, we printed the number of patients still at risk at each time point according to
treatment arm (nrisk = T). Moreover, the result of the log-rank test and the hazard ratio
of Arm 2 vs. Arm 1 is also printed (info = T, pos.info = c(6, 0.8)). The hazard ratio
(Arm 2 vs. Arm 1) equals 2.86 with 95% confidence interval (1.16 − 7.09) and the result of
the log-rank test is p = 0.018.
R> tudd1 <- TUDD(dataqol_final, score = "QL", MCID = 5, ref.init = "baseline",
+ ref.def = "def1")
R> ttd_1 <- merge(tudd1, unique(dataqol_final[, c("Id", "Arm")]))
R> plotTTD(ttd_1$time.5.QL, ttd_1$event.5.QL, ttd_1$Arm, nrisk = T, nevent = F,
+ group.names = c("Arm 1", "Arm 2"), t = seq(0, 10, 2), info = T,
+ pos.info = c(6, 0.8), xlab = "time (months)", ylab = "probability (%)")
Write all the results of a time to deterioration analysis in a CSV file. All informa-
tion regarding TTD or TUDD analysis can also be output to a CSV file such as the number
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MCID = 5 points
TTD baseline
N (events) Median (CI 95%) Log-rank HR (CI 95%)
QL
Arm 1 20 (11) 3.61 (1.84–NA) p = 0.136 1
Arm 2 18 (13) 1.81 (1.54–NA) 1.87 (0.81–4.31)
PF
Arm 1 20 (10) 1.84 (1.71–NA) p = 0.634 1
Arm 2 20 (11) 1.82 (1.54–NA) 1.23 (0.52–2.93)
FA
Arm 1 20 (8) 6.74 (1.74–NA) p = 0.35 1
Arm 2 20 (11) 4.67 (1.64–NA) 1.55 (0.61–3.92)
Table 8: The CSV file created with the application of the write.TTD function.
of events and the effect size of the treatment effect with hazard ratio and log-rank test with
write.TTD() or write.TUDD() commands available in QoLR package.
For example, the following command creates a CSV file named "file_TTD_baseline" which
is located in the current directory of your R session. You can also specify the directory in the
file parameter. With this command, we studied the TTD of QL, PF and FA scores with a
5-point and a 10-point MCID as compared to the baseline score.
Table 8 is an extract of this file for a 5-point MCID.
R> write.TTD(dataqol_final, score = c("QL", "PF", "FA"), order = c(1, 1, 2),
+ MCID = c(5, 10), group = "Arm", names.group = c("Arm 1", "Arm 2"),
+ sensitivity = FALSE, file = "file_TTD_baseline")
For example, in arm 1 and arm 2, 11 and 13 patients respectively experienced a deterioration
of at least 5 points in the QL score as compared to the baseline score, among the 38 patients
included (20 patients in arm 1, 18 patients in arm 2, no data were available for two patients).
The median TTD was 3.61 months with a 95% confidence interval (1.81–NA) for arm 1 and
1.81 months with a 95% confidence interval (1.54–NA) for arm 2 (log-rank p = 0.136). The
univariate Cox hazard ratio of arm 2 vs. arm 1 was 1.87 with a 95% confidence interval
(0.81–4.31).
4. Conclusion and outlook
The QoLR package is the first R package dedicated to the analysis of HRQOL. The imple-
mentation of the time to deterioration definitions in a HRQOL score allows the dissemination
of these approaches in order to achieve the goal of standardization of longitudinal HRQOL
analysis in oncology clinical trials.
QoLR will be updated as new modules are developed by the EORTC HRQOL group. The
package will be completed over time, by some simulation algorithms of longitudinal HRQOL
data with intermittent or monotone missing data of type Missing Completely At Random
or Missing Not At Random for example. Other programs will make it possible to print the
results of univariate and multivariate Cox analyses in a CSV file. Moreover, an ongoing
Journal of Statistical Software 27
project is investigating the presence of competitive risk between events. The current package
will then be expanded by the addition of competitive risk models. Finally, the time to
deterioration approach can be implemented using SAS software (SAS Institute Inc. 2011) to
allow researchers not familiar with R software to apply this longitudinal analysis method.
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